Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.

NCT02037373 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT02037373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02037373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Lead sponsor
Octapharma
Phase
Observational
Overall status
Terminated
Start date
August 31, 2015
Completion date
February 28, 2018
Enrollment
43 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

coagulopathy, endstage liver disease